Product
Ambitions
The development of the product, QR-02, is rooted in scientific evidence that highlights the disruption of QR-02 in treating patients with oral leukoplakia.
Because oral leukoplakia further negatively attributes to enhancing the risk of patients developing abnormal, and potentially cancerous, cell growth (dysplasia), QR-02
holds an added benefit in reducing the risk of dysplasia.
Background
Oral leukoplakia is a potentially cancerous white patch or plaque in the mouth, strongly linked to smoking. The edges of the lesion are typically abrupt and the lesion changes.
Oral leukoplakia also has dysplasia which highlights the severity of the disorder and is a marker of disease progression. Dysplasia is abnormal cell growth, a precancerous condition more serious than normal cell overgrowth (hyperplasia). In adults, precancerous dysplasia may not always turn into cancer, but there’s a risk it could.
Key Statistics/
Information on
Oral Leukoplakia
Based on prevalence estimates of 2% of the general population there are an 15M leukoplakia patients in the US (6.6M) and EU (8.9M) combined.
Approximately 80% of leukoplakia lesions occur in the oral cavity and could be treated by a gel (as determined by market research).
Cancers of the oral cavity (lip, oral tongue, gingiva, floor of mouth, palate, and other mouth, including buccal mucosa) account for approximately 250 000 annual incident cases. Incidence of oral cancer was substantially elevated in patients with oral leukoplakia), including enormously high risk in the first year following a leukoplakia diagnosis.
based on prevalence estimates of 2%
of the general population
The percentage of people affected with
Oral Leukoplakia & Oral Canceris estimated at 1-3%
Oral Leukoplakia
& Oral Cancer:
Prevalence
& Progression
Incidence of oral cancer was substantially elevated in patients with oral leukoplakia. Individuals with oral leukoplakia bear a substantially elevated risk of oral cancer, with enormously high risk within 1 year of a precancer and notably elevated risk beyond 1 year.
The 5-year competing risk–adjusted absolute risk of oral cancer in patients with oral leukoplakia was 3.3% absolute risks were higher for leucoplakias that were biopsied compared with leucoplakias that were not biopsied.
Treatment recommendations depend on features of the lesion. follow up at three-to-six-month intervals may be sufficient.
The percentage of people affected is estimated at 1-3%.
Leukoplakia becomes more common with age, typically not occurring until after 30. Rates may be as high as 8% in men over the age of 70. with time.